Tarsons Products Ltd
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals[1]
- Market Cap ₹ 2,285 Cr.
- Current Price ₹ 429
- High / Low ₹ 574 / 389
- Stock P/E 47.4
- Book Value ₹ 118
- Dividend Yield 0.47 %
- ROCE 10.2 %
- ROE 8.62 %
- Face Value ₹ 2.00
Pros
Cons
- The company has delivered a poor sales growth of 9.18% over past five years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 6.92% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Part of BSE Healthcare BSE Allcap BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
179 | 176 | 229 | 301 | 283 | 277 | 293 | |
107 | 107 | 125 | 148 | 153 | 174 | 196 | |
Operating Profit | 72 | 69 | 103 | 153 | 130 | 103 | 97 |
OPM % | 40% | 39% | 45% | 51% | 46% | 37% | 33% |
6 | 4 | 5 | 8 | 12 | 14 | 25 | |
Interest | 7 | 6 | 3 | 4 | 4 | 10 | 15 |
Depreciation | 15 | 14 | 14 | 22 | 29 | 38 | 41 |
Profit before tax | 56 | 53 | 92 | 135 | 109 | 69 | 65 |
Tax % | 30% | 24% | 25% | 25% | 26% | 26% | |
39 | 41 | 69 | 101 | 81 | 51 | 48 | |
EPS in Rs | 2,027.06 | 2,108.74 | 3,583.25 | 18.92 | 15.17 | 9.63 | 9.06 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 21% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 7% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 6% |
3 Years: | -9% |
TTM: | -21% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -14% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 18% |
3 Years: | 16% |
Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0 | 0 | 0 | 11 | 11 | 11 | 11 |
Reserves | 135 | 197 | 244 | 479 | 559 | 610 | 618 |
65 | 36 | 34 | 22 | 111 | 257 | 244 | |
12 | 15 | 18 | 33 | 46 | 76 | 109 | |
Total Liabilities | 212 | 249 | 296 | 544 | 726 | 953 | 982 |
89 | 92 | 120 | 189 | 225 | 252 | 399 | |
CWIP | 7 | 19 | 22 | 32 | 119 | 267 | 217 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
116 | 137 | 153 | 323 | 382 | 434 | 366 | |
Total Assets | 212 | 249 | 296 | 544 | 726 | 953 | 982 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
51 | 64 | 68 | 83 | 76 | 105 | |
-34 | -26 | -64 | -138 | -179 | -296 | |
-18 | -14 | -27 | 130 | 85 | 136 | |
Net Cash Flow | -0 | 25 | -23 | 75 | -18 | -55 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 91 | 79 | 75 | 79 | 85 | 94 |
Inventory Days | 333 | 365 | 277 | 478 | 642 | 528 |
Days Payable | 14 | 44 | 35 | 75 | 54 | 42 |
Cash Conversion Cycle | 409 | 400 | 317 | 482 | 672 | 580 |
Working Capital Days | 160 | 149 | 108 | 165 | 205 | 179 |
ROCE % | 27% | 37% | 35% | 19% | 10% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Investor Presentation 3h
-
Board Meeting Outcome for Financial Results For Quarter And Half Year Ended 30Th September, 2024
10h - Board approved unaudited financial results for Q2 FY2024.
- Financial Results For The Quarter & Half Year Ended 30Th September, 2024 10h
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2 Nov - Investor/Analyst Conference Call scheduled for Q2 FY25.
-
Board Meeting Intimation for Consideration & Approval Of Financial Results
28 Oct - Notice of Board Meeting for Q2 financial results.
Annual reports
Concalls
-
Nov 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT REC
-
Aug 2024TranscriptNotesPPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Feb 2024TranscriptNotesPPT
-
Dec 2023TranscriptPPTREC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
India’s Leading Labware Company[1]
One of the leading Indian labware company engaged in designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop
equipment & instruments)